Panelists: Dr. Andrew Armstrong from the Duke Cancer Institute, Dr. J. Jacques Carter from Harvard Medical School and Beth Israel Deaconess Hospital, Dr. Brian Stone from Jasper Urology Associates, Dr. Carlton Barnswell from the Advanced Urology Centers of New York, and Dr. Adam S. Kibel from the Dana-Farber/Brigham and Women’s Cancer Center.
The COVID-19 pandemic greatly impacted prostate cancer detection and treatment. PHEN held a panel discussion in which physicians discussed prostate cancer early detection and strategies for tackling this disease during the pandemic. Patient safety is of paramount importance when facing COVID-19, which is why physicians are only providing diagnostics to the patients at highest risk, explained Dr. Kibel.
Social distancing and keeping the offices from overcrowding is essential. The pandemic has led to a delay in diagnosis by up to six or more months. In some cases, biopsies can also be delayed safely. Communicating with patients during this period is paramount, according to Dr. Carter. Dr. Armstrong discussed how long physicians are comfortable with delaying PSA testing. The panelists also answered audience questions.
#ProstateCancer #ProstateCancerAwareness #COVID19 #Pandemic #ProstateCancerScreening #ProstateCancerDiagnostics #EarlyDetection #ProstateCancerDetection #Coronavirus #CancerScreening #SocialDistancing #PatientSafety
Leave a Reply